Clarivate Epidemiology’s coverage of PV comprises epidemiological estimates of key patient populations in the major European pharmaceutical markets (Austria, Belgium, Czech Republic, Denmark, Finland, Greece, Netherlands, Norway, Poland, Portugal, Sweden, and Switzerland). We report both the diagnosed incidence and prevalence of PV for each country, as well as annualized case counts projected to the national population.
Clarivate Epidemiology’s forecast will answer the following questions:
How many people in each of the major European pharmaceutical markets have been formally diagnosed with PV; how many are newly diagnosed each year?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of PV over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts three patient populations, as follows:
Diagnosed Prevalence of Pemphigus Vulgaris per 100,000 People in 2021 and 2041
Relative Sizes of the Contributing Factors to the Trend in Diagnosed Prevalent Cases of Pemphigus Vulgaris over the Next 20 Years
Diagnosed Incident Cases
Diagnosed Prevalent Cases
Diagnosed Incident Cases by Severity
Studies Included in the Analysis of Pemphigus Vulgaris
Studies Excluded from the Analysis of Pemphigus Vulgaris
Risk/Protective Factors for Pemphigus Vulgaris
Utsav Patel, M.P.H.,is an associate epidemiologist at Clarivate. Previously, he worked as a graduate research assistant at City University of New York, where he conducted multi-omics investigations into cancer study funded by the National Institutes of Health. He obtained his M.P.H. in epidemiology and biostatistics from City University of New York.
T.J. Arndt, M.P.H., C.P.H.
Thomas J. Arndt, M.P.H., C.P.H., is a senior epidemiologist at Clarivate. He earned his master’s degree in public health at the University of Florida, where he conducted an internship developing a clinical model for noninvasively screening for nonalcoholic steatohepatitis (NASH). He also holds a B.S. in microbiology and cell science and a B.A. in Spanish, both from the University of Florida. While studying at the University of Florida, Mr. Arndt worked in two physiology-based research labs focusing on maternal and fetal stresses during pregnancy and parturition.